The open-label, dose-escalation trial also showed that eight of 10 patients with secondary progressive disease who were treated for 12 weeks showed some improvement in their signs and symptoms...Transition Therapeutics Inc., of Toronto, reported data from a Phase I single-ascending dose-escalation study of TT=401, a once-weekly peptide designed to lower blood glucose levels in patients with Type II diabetes and accompanying obesity
The dose-escalation trial is designed to enroll approximately 20 ATTR patients, who will be enrolled into cohorts of increasing doses and will receive the drug once every four weeks for two cycles...The placebo-controlled, single-dose escalation study tested the compound in 25 patients with mild to moderate lupus
The Phase I dose-escalation portion will evaluate the safety and tolerability of the combination in up to 36 patients with any BRAF-mutant cancer, while the Phase II portion will compare antitumor activity of PX-866 plus vemurafenib vs
The dose-escalation trial will evaluate the safety and pharmacokinetics of mibefradil when sequentially administered with temozolomide in an approach Tau calls interlaced therapy
The dose-escalation trial is expected to enroll up to 24 patients in up to five cohorts with final safety and pharmacokinetic data expected in the first half of 2013
Up to 30 patients are expected to enroll in the dose-escalation portion of the study, with up to 60 additional patients enrolled in the study's biomarker exploration component
Data from the dose-escalation study, GIHU004, indicated the induction of long-lasting memory T-cell responses after a single immunization of DermaVir, the company's lead vaccine candidate in HIV
Novelos Therapeutics Inc., of Madison, Wis., said it completed the first cohort in its Phase Ib dose-escalation trial of cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in patients with advanced solid tumors...The company is set to start a Phase I/II study this summer, enrolling up to 36 patients with B-cell lymphomas in the Phase I dose-escalation portion and up to 77 patients, stratified by B-cell lymphoma subtype, in the second portion
The trial was a randomized, placebo-controlled, single-dose escalation study...The Phase II study follows the positive findings of a Phase I dose escalation study in MDS patients treated with orally administered rigosertib
The company decided to add a second, higher-dose group based on promising preliminary data from the first dose group as well as dose-escalation data from other trials of the drug indicating that higher doses of FG-3019 appeared to be associated with more robust biological and clinical response
The companies plan a Phase Ib dose-escalation study at five sites in the Russian Federation of the oral formulation of CBLC137 in advanced solid tumors that are resistant or refractory to standard of care...The study includes a dose-escalation arm of up to 36 patients divided into six cohorts and a dose-confirmation arm with an additional nine to 12 patients to be enrolled at the selected therapeutic dose
Boston Therapeutics Inc., of Manchester, N.H., reported that no safety concerns were observed based on interim data analysis from an open-label, dose-escalation, crossover trial testing PAZ320, a nonsystemic chewable complex carbohydrate-based compound aimed at reducing post-meal elevation of blood glucose, in Type II diabetics...The open-label, dose-escalation trial is expected to enroll up to 24 patients and will evaluate safety and tolerability, as well as characterize the pharmacokinetic
The Phase I/II study will involve a dose-escalation portion, followed by an expansion cohort testing the drug in NSCLC patients who have failed EGFR-directed therapies such as Tarceva (erlotinib, Astellas Pharma Inc. and Roche AG) and Iressa (gefitinib, AstraZeneca plc) and have developed the T790M mutation
Jennerex Inc., of San Francisco, said it treated the first patient in a Phase I/II trial of JX-594, an engineered oncolytic virus, in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for Erbitux (cetuximab, Eli Lilly and Co.) The two-arm, dose-escalation study, expected to enroll up to 42 patients, will test the drug as a monotherapy and in combination with irinotecan, and endpoints will include safety, dose
The open-label, dose-escalation study will assess safety, immunogenicity, pharmacokinetics, biomarkers and initial signals of efficacy